The FDA has granted emergency use authorization to the first COVID-19 treatment option that uses a pair of antibodies to neutralize the novel coronavirus.
WesTech Engineering, Inc., an employee-owned company, and JS&S (Water Holdings) Inc., a subsidiary of John Swire & Sons Limited ("Swire"), are pleased to announce they have signed a Membership Interest Purchase Agreement (MIPA) for the sale of WesTech to Swire. Terms of the MIPA are confidential and the offer is subject to shareholder approval.
In this episode of Motley Fool Money, Chris Hill chats with Motley Fool analysts Andy Cross and Jason Moser about the latest headlines and earnings reports from Wall Street. They've got news on some retail stock gains, home improvement stocks falling despite posting profits, and a kitchenware and home furnishing giant that crushed earnings estimates and hit an all-time high.
Asian markets rallied Wednesday following a blockbuster performance on Wall Street as vaccine successes and easing US political uncertainty boosted investor confidence in the economic recovery. Signs that infection rates in Europe are slowing enough to allow some countries to ease lockdown measures added to the sense of hope across trading floors.However, still-high death numbers and a pick-up in new cases in several Asian nations tempered the excitement.Hopes for a worldwide rollout of an inoculation were given an extra lift Tuesday when Russia said its Sputnik V drug had shown to be 95 percent effective, making it the fourth that could be available soon after similar positive announcements from Pfizer/BioNTech, Moderna and AstraZeneca."While the logistical challenges will still be immense, the geographic diversity of the possible suppliers is promising," said Gorilla Trades strategist Ken Berman."The fact that several European outbreaks seemed to have peaked was another bullish catalyst... as even though the US wave is lagging behind the European one by several weeks, the end of the current domestic outbreaks could be closer than previously thought."The medical breakthroughs come as political uncertainty appears to be waning in Washington after government officials began the crucial transition process paving the way for Joe Biden to enter the White House.While he still denies losing the November 3 election, Donald Trump's decision to sign off on the move by the General Services Administration (GSA) was effectively an admission of defeat.Investors are also upbeat about Biden's cabinet picks so far, particularly former Federal Reserve boss Janet Yellen's nomination as treasury secretary, with optimism she can work well with current central bank head Jerome Powell.Onwards and upwards "A Yellen-Powell policy combination in government and the central bank is as dovish and positive as one can imagine for risk assets," said Axi's Stephen Innes. "Even if Congress balks at further significant fiscal stimulus... investors will position for high-profile policymaker pressure starting to bear fruit."Wall Street's three main indexes ended more than one percent higher Tuesday, with the Dow closing above 30,000 for the first time and the S&P 500 also notching up a record.The rally seeped through to Asia, which was already enjoying a broadly healthy week.Tokyo, Hong Kong and Jakarta were all more than one percent higher, while Shanghai, Sydney, Singapore, Seoul, Taipei and Wellington were also well up.The gains were led by energy firms and tourism-linked companies such as airlines as traders bet on a boost to business as the world slowly returns to some sense of normality.Expectations of a rise in demand supported oil prices, which have jumped around a quarter over the past month and are now sitting at levels not seen since March, before they crashed into negative territory.High-yielding currencies such as the South Korean won, South African rand, Russian ruble and Australian dollar were all up against the dollar, thanks to improving confidence in riskier assets."Looking three to six months out, we do think the recovery will maintain its momentum," Anna Han, at Wells Fargo Securities, told Bloomberg TV. "When you see that reflation trade coming back, it's telling you that investors are gaining confidence in growth prospects looking forward."(AFP)
Each year, the Grammy nominations inspire criticism and head-scratching — and the nominees for the 2021 ceremony on January 31 are no different. As usual, there are surprise nods (Coldplay for album of the year? Really?) and snubs that leave us asking “But what about…?” (poor The Chicks). This year, though, in a post-George Floyd […]
The Genomics Market will grow by USD 17.23 bn during 2020-2024
Fox News legal analyst Gregg Jarrett and Rep. Devin Nunes offer analysis and reaction on 'Hannity'
Tourists slipped and slid down the ramparts of the Great Wall of China on November 21 as the first snow of the 2020 season arrived in Beijing.Video posted to Weibo showed people sliding down the wall while other tourists attempted to climb without falling over in the slippery conditions.Local media reported tourists embracing scenic spots in Beijing as the snow created a wintry landscape. Credit: cxjzvvv via Storyful
As expectations grow that the first Covid-19 jabs will be administered in a matter of weeks, German glassmaker Schott is quietly doing what it has been for months: churning out vials that will hold the vaccine.
Asian markets rallied Wednesday following a blockbuster performance on Wall Street as vaccine successes and easing US political uncertainty boosted investor confidence in the economic recovery.
Fox News contributors Emily Compagno and Joe Concha join 'Hannity' with reaction
EQS-News / 25/11/2020 / 11:10 UTC+8New dosage form (or formulation) of anticancer drug MPB-1734 passes the US FDA clinical I/IIa IND application The new anticancer drug of MPB-1734 developed by MegaPro Biomedical has passed the US FDA's review, and the IND has been approved for the clinical phase I/IIa trial. The development of new formulations of MPB-1734 is based on the nano micelle technology platform of MegaPro Biomedical, which enhances accumulation on a tumor site, while reducing the side effects of conventional cancer drugs to provide a better efficacy/safety benefits.Cell and animal tests have shown that the drug has an impressive inhibitory effect on drug-resistant malignant tumors. Therefore, the new formulation of the MPB-1734 anticancer drug is expected to provide better treatment options for cancer patients. The results of pre-clinical studies of the MPB-1734 anticancer drug showed that the maximum tolerated dose was 3 times as that of the original drug, and the bone marrow suppression after administration was milder than that of the original drug as well, which helped patients complete the course of treatment while maintaining immunity and enhancing efficacy. The results of pre-clinical studies also showed that the new formulation of MPB-1734 anti-cancer drug can effectively inhibit tumor growth and increase the survival rates of diseased animals. At the same time, it can increase tumor antigen presentation so that the animal's immune system can learn and identify malignant tumors; in the animal experiment group with immune checkpoint inhibitors (anti-PD-1), the combined use of low-dose MPB-1734 new formulation anti-cancer drugs can effectively suppress and reduce malignant tumors. In the future, it will be developed as combination therapy with immunotherapy agents to achieve a synergy effect. The Phase I/IIa clinical trial of the new formulation of MPB-1734 anticancer drug will be carried out in a multinational and multicenter clinical trial. The anticipated target patients would be in the late stage of having advanced solid tumors. MPB1734 clinical trial is expected to begin in 2021, and to be completed by the end of 2023. About MegaPro BiomedicalMegaPro Biomedical is a new drug development company with nano-drugs as its core. It uses nano-particles and nano-micelle as its technology platform. Currently, its nano-particle product MPB-1523 (liver cancer MRI imaging agent) has completed the phase II clinical trial. The second nanoparticle product MPB1514 (iron supplement for iron deficiency anemia) is under the phase II trial since 2019.. Using nano micelle technology platform to build an anti-cancer drug candidate, the new formulation of MPB-1734 anti-cancer drug has also completed the US FDA clinical I/IIa phase IND application, and MegaPro is expected to launch more product lines with its highly competitive nanotechnology platform and accelerate the development of products to clinical use through international cooperation. As for further information regarding the company, please visit http://www.megaprobio.com .File: New dosage form (or formulation) of anticancer drug MPB-1734 passes the US FDA clinical I/IIa IND application25/11/2020 Dissemination of a Marketing Press Release, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
A federal judge has thrown out a lawsuit that accused the Hollywood Foreign Press Association of using its clout to control the market for overseas entertainment coverage. In a ruling issued on Friday, Judge Stanley Blumenfeld tossed the lawsuit brought by Kjersti Flaa, a Norwegian reporter who alleged that she had been repeatedly denied membership […]
The CEO of a Midwest hospital system is out of a job days after he sent a bizarre letter to employees in which he said he would not be wearing a mask because he believed he was immune after contracting COVID-19.Kelby Krabbenhoft, who is not a doctor, had headed Sanford Health since 1996. Just a a few weeks ago, after the announcement of a merger with Intermountain Health, he said he planned on staying another 18 months.But that all changed after his email—which was shocking enough that Sanford officials quickly put out a statement disavowing it. In the note, he said he had recovered from the coronavirus and was now immune for seven months—even though medical experts say it’s not clear how long immunity lasts.Even more disturbing, Krabbenhoft informed employees he would not be wearing a mask in the office, even though Sanford recommends masks and is headquartered in one of the nation’s worst hot spots.Hospital Lurches Away From CEO’s Vow That He Won’t Mask Up After COVID Infection“For me to wear a mask defies the efficacy and purpose of a mask and sends an untruthful message that I am susceptible to infection or could transmit it,” Krabbenhoft wrote.“I have no interest in using masks as a symbolic gesture,” he added “My team and I have a duty to express the truth and facts and reality and not feed the opposite.”He even seemed to question the wisdom of wearing masks outside the operating room.“The ‘on-again, off-again’ behavior of mask use by the general population violates every notion of serious infectious management that I was trained to adhere to, so some of this is absurd,” he wrote.A spokesman for the health-care system, which operates hundreds of rural hospitals and clinics and employs some 50,000 people, put out a damage control statement that the email only represented “personal opinions about the virus” and not company policy.That was followed up by a statement from other top Sanford executives who wrote: “We know that words matter, and words have power, and we regret that the message left many frustrated and disappointed.”On Tuesday evening came another announcement that Krabbenhoft and Sanford had agreed to part ways. The dethroned CEO told KELO-TV that the mask letter was not the impetus.“If there was ever a time for a guy, who’s been through what I’ve been through, this is a great time to say goodbye,” he said.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
The list of Week 13 college football games to be postponed or canceled due to COVID-19 continues to grow.
Nivar is the second cyclone in the Bay of Bengal this year.
Handcuffed asylum seekers 'paraded like criminals' in Australian hospitals, doctors sayDoctors for Refugees group condemns the shackling and says it obstructs medical examinations as well as causing extreme humiliation
More than 200 million Nigerians will slide further into poverty as the coronavirus pandemic has sent oil prices tumbling and pushed Africa's largest economy into recession.
Good morning, everyone, and thank you for joining Ferroglobe's third-quarter 2020 conference call. Joining me today are Marco Levi, our chief executive officer; Gaurav Mehta, EVP of strategy and investor relations; and Jorge Lavin, group controller. Risk factors that could cause actual results to differ materially from these forward-looking statements can be found in Ferroglobe's most recent SEC filings and exhibits to those filings, which are available on our website, www.ferroglobe.com.
SPOILER ALERT: Do not read if you have not yet watched the Nov. 24 episode of "The Bachelorette." Sixteen men remained in hopes of pursuing titular Bachelorette Tayshia Adams on Tuesday's episode of “The Bachelorette.” Those men reflected on the previous dates poolside, but were interrupted by the arrival of host Chris Harrison. “Lesson learned […]
Chinese ride-sharing company Didi began rolling out a service in Mexico this week to let female drivers select only other women as their passengers, a move aimed at encouraging their safety as the country confronts worsening gender violence. Called "Didi Mujer," or Didi Woman, the program is being piloted in Mexico City, Guadalajara, Monterrey and Tijuana, and Didi hopes if more women join the platform, passengers eventually will be able to exclusively choose female drivers. Didi's rival, Uber Technologies Inc, earlier this month also launched an option for female drivers in Mexico to select only women passengers, in line with a similar Uber program in Saudi Arabia.